Drugs / ADRIFORANT
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00992342 | Nov 2009 → Mar 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00856687 | Apr → Dec 2009 | asthma | Pfizer | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT03948334 | Apr 2019 → Jul 2020 | atopic eczema | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT03517566 | Nov 2018 → Jul 2020 | atopic eczema | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT02618616 | Jan → Dec 2016 | psoriasis | Ziarco Pharma Ltd | Completed | No outcome recorded |
| Phase 2 | NCT02424253 | May 2015 → Jan 2016 | atopic eczema | Ziarco Pharma Ltd | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADRIFORANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL1915540 ↗ |
| Known as | NVP-ZPL389-NX | ChEMBL registry synonym — accepted as the source's own label CHEMBL1915540 ↗ |
| Known as | PF-03893787 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00992342 ↗ |
| Known as | PF-3893787 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1915540 ↗ |
| Known as | ZPL-389-NX | ChEMBL registry synonym — accepted as the source's own label CHEMBL1915540 ↗ |
| Known as | ZPL-3893787 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02618616 ↗ |
| Known as | ZPL389 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03517566 ↗ |
| Action | Inhibit | “Histamine H4 receptor antagonist” CHEMBL1915540 ↗ |
| Modality | Small molecule | — CHEMBL1915540 ↗ |
| Route | Oral | “Oral, two doses 12 hours apart” NCT00856687 ↗ |
| Target | HRH4 | “Histamine H4 receptor antagonist” CHEMBL1915540 ↗ |